Prof. Jilong Yang, the first USCACA – NFCR Scholar (2010) is to speak at AACR conference

Submitted by admin on Sun, 09/18/2016 - 13:50


Prof. Jilong Yang, the first US Chinese Anti‐Cancer Association (USCACA) – National Foundation for Cancer Research (NFCR) Scholar (2010) is to speak at AACR conference “New Horizons in Cancer Research”, Nov 2-5, Shanghai, China. Please also see Yang’s new book – “The Knowledge of Sarcoma – 认识肉瘤”


Introduction to Prof. Jilong Yang
Prof. Jilong Yang, the first US Chinese Anti‐Cancer Association (USCACA) Scholar (2010), is an excellent oncological surgeon specializing in sarcoma. He has extensive experience conducting sarcoma genomic research. He has been a Principal Investigator on a number of grants funded by National Natural Science Foundation of China (NSFC) and other funding agencies. He is well published in high impact journals such as Molecular & Cellular Proteomics, Clinical Cancer Research, Eur J Cancer, Cancer, Curr Opin Oncol, J Hepa & Oncol, Oncotarget, and Cancer Lett. As a Ph.D. Mentor and the Vice Director of the Department of Bone and Soft Tissue Sarcoma, Tianjin Medical University Cancer Hospital, he is in charge of several clinical trials on targeted therapy for advanced sarcoma patients.


A presentation about Sarcoma by Dr. Jilong Yang
Sarcoma is a rare cancer type originated from mesenchymal tissues with unknown molecular mechanism of etiology and pathogenesis. It remains a challenge for current treatment strategies. As a nationally recognized sarcoma physician scientist and an active member of USCACA, Prof. Jilong Yang has been invited by AACR to present a 30-mim talk at the upcoming Shanghai conference - New Horizons in Cancer Research: Delivering Cures through Cancer Science (http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=93#.V9...). In this presentation, Dr. Yang will give an overview on the molecular changes and new targets for the treatment of sarcoma based on his research over the last several years in the area of translational research and precision medicine. In this next generation sequencing era, targeted therapy based on precision medicine would greatly benefit the sarcoma patients.


“ The Knowledge Of Sarcoma”
With the support of Prof. Wei Zhang, former Director of the Cancer Genomics Core Lab at the University of Texas MD Anderson Cancer Center and the Chairman of the Board of USCACA, Prof. Jilong Yang has worked with Dr. Bruce Shriver, the Editor-in-Chief of the Electronic Sarcoma Update Newsletter (ESUN), published a book to address a wide variety of issues in soft tissue and bone sarcomas in China. This has been a large undertaking which will be extremely useful to the Chinese-speaking sarcoma community.



Group: 
Events and Activities
News Category: 
Cancer News